| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
There is no specific biological target for this reverse peptide. It is not recognized by the same receptors as Abeta1-42 and does not bind to the prion protein or other Abeta-binding proteins. It serves as a non-aggregating control.
|
|---|---|
| ln Vitro |
In cell-free assays, Abeta42-1 does not form amyloid fibrils under conditions where Abeta1-42 rapidly aggregates. Thioflavin T (ThT) fluorescence assays show no increase in signal over time. It also does not exhibit neurotoxicity in neuronal cultures, unlike Abeta1-42.
|
| ln Vivo |
In vivo, Abeta42-1 is used as a control peptide in animal models. When injected into mouse brains, it does not induce amyloid plaque deposition, neuroinflammation, or cognitive deficits, confirming its inert nature in comparison to the pathological Abeta1-42.
|
| Enzyme Assay |
For ThT aggregation assay: Abeta42-1 is dissolved in hexafluoroisopropanol (HFIP), dried, then resuspended in 10 mM NaOH, diluted into PBS (pH 7.4) to 50 uM. ThT (10 uM) is added, and fluorescence (Ex/Em 440/480 nm) is measured every 5-30 minutes at 37degC for 24-72 hours. No aggregation is observed.
|
| Cell Assay |
Primary cortical neurons or SH-SY5Y cells are treated with Abeta42-1 (1-50 uM) for 24-72 hours. Cell viability is measured by MTT or LDH assay. In contrast to Abeta1-42, Abeta42-1 shows no significant cytotoxicity. It can be used as a negative control alongside the active peptide.
|
| Animal Protocol |
For in vivo control, Abeta42-1 (e.g., 5 ug in 2 uL PBS) is injected intracerebroventricularly (ICV) into mice or rats. After 1-4 weeks, animals are subjected to behavioral tests (Morris water maze, novel object recognition). No cognitive impairment is observed, confirming it as a negative control.
|
| ADME/Pharmacokinetics |
PK properties for Abeta42-1 are similar to those of Abeta1-42: rapid clearance from the brain after ICV injection (half-life ~30-60 minutes) and degradation by proteases. It does not accumulate in plaques. Formulation is in PBS or saline.
|
| Toxicity/Toxicokinetics |
General toxicity of Abeta42-1 is very low, as it does not form toxic oligomers. Acute toxicity studies in rodents show no adverse effects at typical experimental doses (up to 50 ug ICV). Standard handling for peptides (avoid inhalation, use gloves) is recommended.
|
| References | |
| Additional Infomation |
Reverse-sequence amyloid-beta peptides are standard negative controls in Alzheimer's research. Abeta (42-1) is commercially available as a trifluoroacetate (TFA) salt. It is used to validate that observed effects are specific to the native sequence and not due to non-specific peptide properties. This product is for research use only.
|
| Related CAS # |
β-Amyloid (42-1), human;317366-82-8
|
|---|---|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product is not stable in solution, please use freshly prepared working solution for optimal results. (2). Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~100 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
